In July 2026, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended the approval of three medicinal products for the treatment of lipid disorders (https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-july-2026):
Obicetrapib inhibits cholesteryl ester transfer protein (CETP). CETP inhibition substantially increases HDL cholesterol while reducing LDL cholesterol and apolipoprotein B. Obicetrapib is supplied as a film-coated tablet and has been recommended for approval both as a single active substance under the brand name Ubeslo® (https://www.ema.europa.eu/en/medicines/human/EPAR/ubeslo) and in a fixed-dose combination with ezetimibe under the brand name Evlarco® (https://www.ema.europa.eu/en/medicines/human/EPAR/evlarco). Both formulations are taken once daily.
Further details on the mechanism of action, clinical-trial results and adverse effects of obicetrapib are provided in the chapter “Lipid Metabolism: Obicetrapib.”
The CHMP also recommended the approval of another PCSK9 inhibitor, lerodalcibep, under the brand name Lyrokaul® (https://www.ema.europa.eu/en/medicines/human/EPAR/lyrokaul). PCSK9 normally binds to LDL receptors on the surface of liver cells and directs the receptors towards lysosomal degradation. This reduces the number of LDL receptors that can return to the cell surface and remove LDL particles from the bloodstream. By binding to and inhibiting PCSK9, lerodalcibep preserves LDL receptors and thereby increases hepatic clearance of LDL cholesterol.
The monoclonal antibodies evolocumab and alirocumab have been available as potent PCSK9 inhibitors since 2015. Inclisiran is another PCSK9-targeted treatment. It is a small interfering RNA (siRNA) therapy that suppresses PCSK9 production in the liver, thereby increasing the number of LDL receptors available to clear LDL cholesterol from the blood.
Lerodalcibep is administered by subcutaneous injection only once monthly. Further details on its mechanism of action, clinical-trial results and adverse effects are provided in the chapter “Lipid Metabolism: Lerodalcibep.”